Literature DB >> 16234113

[Diagnostic value of combined detection of TPS, CA153 and CEA in breast cancer].

Hang Zheng1, Rong-cheng Luo.   

Abstract

OBJECTIVE: To study the diagnostic value of combined detection of the 3 tumor markers, namely tissue polypeptide specific antigen (TPS), cancer antigen 153 (CA153), and carcino embryonic antigen (CEA), in patients with breast cancer.
METHODS: The serum levels of TPS, CA153 and CEA were determined by enzyme-linked immumosorbent assay in 90 patients with breast cancer and 30 healthy adults.
RESULTS: The serum levels of 3 tumor markers in breast cancer patients were significantly higher than those in the control group (P<0.01). The sensitivity of TPS to breast cancer was 87.7% with specificity of 90.0%. The sensitivity and specificity of CA153 to breast cancer was 55.6% and 93.3%, and those of CEA was 45.8% and 96.7%, respectively. The sensitivity of the 3 tumor markers in combination was 100% in breast cancer diagnosis.
CONCLUSION: TPS, CA153 and CEA have diagnostic value in breast cancer and possess obvious complementarity, and their combined detection can significantly improve the sensitivity of breast cancer diagnosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16234113

Source DB:  PubMed          Journal:  Di Yi Jun Yi Da Xue Xue Bao        ISSN: 1000-2588


  8 in total

1.  Detection and identification of potential biomarkers of breast cancer.

Authors:  Yuxia Fan; Jiachen Wang; Yang Yang; Qiuliang Liu; Yingzhong Fan; Jiekai Yu; Shu Zheng; Mengquan Li; Jiaxiang Wang
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-17       Impact factor: 4.553

2.  Screening serum hepatocellular carcinoma-associated proteins by SELDI-based protein spectrum analysis.

Authors:  Jie-Feng Cui; Yin-Kun Liu; Hai-Jun Zhou; Xiao-Nan Kang; Cheng Huang; Yi-Feng He; Zhao-You Tang; Toshimasa Uemura
Journal:  World J Gastroenterol       Date:  2008-02-28       Impact factor: 5.742

3.  A novel panel of stool-based DNA biomarkers for early screening of colorectal neoplasms in a Chinese population.

Authors:  Minghao Sun; Jie Liu; Hao Hu; Peng Guo; Zhili Shan; Hengying Yang; Junyi Wang; Wen Xiao; Xiaojun Zhou
Journal:  J Cancer Res Clin Oncol       Date:  2019-08-27       Impact factor: 4.553

4.  Elevation of serum CEA and CA15-3 levels during antitumor therapy predicts poor therapeutic response in advanced breast cancer patients.

Authors:  Yue Yang; Huijuan Zhang; Mingyan Zhang; Qingwei Meng; Li Cai; Qingyuan Zhang
Journal:  Oncol Lett       Date:  2017-10-10       Impact factor: 2.967

5.  Assessing Clinical Significance of Serum CA15-3 and Carcinoembryonic Antigen (CEA) Levels in Breast Cancer Patients: A Meta-Analysis.

Authors:  Yijie Fu; Hui Li
Journal:  Med Sci Monit       Date:  2016-09-06

6.  The diagnostic value of combined detection of genetic markers and serum protein markers on breast cancer.

Authors:  Qiujian Li; Lu Li
Journal:  Saudi J Biol Sci       Date:  2018-11-05       Impact factor: 4.219

7.  The Expression Level of BRCA2 and Its Changes during Chemotherapy in Patients with Different Pathological Types of Mammary Cancer.

Authors:  Yu Huang; Min Luo; Junqing Huang; Shaoxin Huang; Liuxia Wei; Yumei Zhang; Zhiming Zhang
Journal:  Iran J Public Health       Date:  2019-09       Impact factor: 1.429

8.  A dried blood spot mass spectrometry metabolomic approach for rapid breast cancer detection.

Authors:  Qingjun Wang; Tao Sun; Yunfeng Cao; Peng Gao; Jun Dong; Yanhua Fang; Zhongze Fang; Xiaoyu Sun; Zhitu Zhu
Journal:  Onco Targets Ther       Date:  2016-03-11       Impact factor: 4.147

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.